Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / CCXI - ChemoCentryx shareholders approve $4.7B merger with Amgen

CCXI - ChemoCentryx shareholders approve $4.7B merger with Amgen

ChemoCentryx Inc.

  • ChemoCentryx shareholders have overwhelmingly approved Amgen's ( NASDAQ: AMGN ) $3.7B acquisition of the compan y.
  • With the acquisition, Amgen ( AMGN ) gains access to Tavneos (avacopan), which is indicated for severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, a group of rare diseases characterized by destruction and inflammation of small vessels.
  • NASDAQ said ChemoCentryx's ( NASDAQ: CCXI ) anticipated last day of trading will be Oct. 19.

For further details see:

ChemoCentryx shareholders approve $4.7B merger with Amgen
Stock Information
Company Name: ChemoCentryx Inc.
Stock Symbol: CCXI
Market: NASDAQ
Website: chemocentryx.com
Menu
CCXI CCXI Quote CCXI Short CCXI News CCXI Articles CCXI Message Board
Get CCXI Alerts

News, Short Squeeze, Breakout and More Instantly...